Trastuzumab (trade name Herceptin), a humanized mAb specific for the human HER2 molecule, was purchased from Roche (Argentine). A biosimilar candidate to trastuzumab, named 5G4 and obtained from murine NS0 myeloma cells, was provided by Development Department of CIM (Havana, Cuba).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.